An open label study to determine the safety, tolerability, excretion balance and pharmacokinetics of [14C] GW856553, administered as a single dose of an oral solution to healthy adult male subjects.

Trial Profile

An open label study to determine the safety, tolerability, excretion balance and pharmacokinetics of [14C] GW856553, administered as a single dose of an oral solution to healthy adult male subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Atherosclerosis; Chronic obstructive pulmonary disease; Depressive disorders; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top